After a 13-month minimum follow-up period, there was a superior overall survival (OS) observed with nivolumab plus chemotherapy, compared to chemotherapy alone, both among patients with tumour cell PD-L1 expression of 1% or greater (median, 15.4 vs. 9.1 months; hazard ratio (HR), 0.54; 99.5% confidence interval [CI], 0.37 to 0.80; p < 0.001) and in the overall population (median, 13.2 vs. 10.7 months; HR, 0.74; 99.1% CI, 0.58 to 0.96; p = 0.002). This evidence concerns the gene CD274 and neoplasm.